Personalized Medicine, Targeted Therapeutics & Companion Diagnostic Market

Personalized Medicine, Targeted Therapeutics & Companion Diagnostic Market


Personalized Medicine: Targeted Therapeutics & Companion Diagnostic Market Analysis & Forecast to 2025- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment provides a comprehensive account of the market size, market forecast, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments.

For Sample Pages or more information email



Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market Analysis & Forecast to 2025- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 

Kelly Scientific forecasts that the companion diagnostic and targeted therapeutic submarkets of the personalized medicine industry will hit over $162 billion in 2021 with a corresponding CAGR of 8.74%.  Currently it is estimated that the companion diagnostic segment is worth a fragment of this, mainly coming from oncology, cardiovascular and infectious disease (HIV/HCV) tests. Advancing technologies within the liquid biopsy market is also driving the market and will see strategic growth over the next five years with a CAGR of 20.6%. The two segments of the liquid biopsy market are tumor cell enrichment products and tumor cell detection technologies.


Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics are more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine reduces the frequency of adverse drug reactions and therefore has a dramatic impact on health economics. Developmental and diagnostic companies benefit from lower discovery and commercialization costs and more specific market subtypes.


This cutting-edge report gives a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 397 pages. The personalized medicine market is presented as follows:

  • By Segment (Targeted therapeutics, Companion Diagnostics)
  • By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy)
  • By Therapy (Cancer, Cardiovascular, Infectious Disease)


Key Opinion Leaders that contributed to interview questions within the report include:

  • Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group
  • Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James’s Hospital and Trinity College Dublin, Ireland
  • Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC
  • Elaine Kenny, PhD, Founder, Elda Biotech, Dublin, Ireland
  • Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine
  • Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine
  • David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine
  • Deborah Phippard, PhD, Vice President, Research, Precision for Medicine
  • Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine


A wealth of financial data & business strategy information is provided including:

  • Company Financials, Sales & Revenue Figures
  • Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies
  • Business Model Strategies for Providers. Provider Systems and Academic Medical Centres
  • Business Model Strategies for Payers & Governments
  • Private and Public Funding and Personalized Medicine Reimbursement
  • Revisions to Current Payment Systems and Intellectual Property
  • How to Gain Market Penetration in the EU
  • Cost-effectiveness and Business Value of Personalized Medicine
  • Consumer genomics and POC market
  • Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
  • Comprehensive Account of Company Product Portfolios & Kits


SWOT, Economic & Regulatory Environment specifics include:

  • Key Strengths, Weaknesses and Threats Influencing Leading Player Position within the Market
  • Technologies Driving the Market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
  • Top Fastest Growing Market Segments and Emerging Opportunities
  • Top Pharmaceutical Companies within the IPM by Market Share and Revenue
  • Comprehensive Product Portfolios, R&D Activity and Pipeline Therapeutics
  • M&A Activity and Future Strategies of Top Personalized Medicine Pharmacos
  • Personalized Medicine Regulation (UK, Germany, France, Spain, Italy)
  • CE-Marked Personalized Medicine/Diagnostic Tests
  • FDA Advances in Personalized Medicine Regulation


This report highlights a number of significant players and influential company’s and gives details of their operations, products, financials and business strategy including:

  • Affymetrix
  • Amgen
  • Astex Pharmaceuticals
  • AstraZeneca
  • Becton Dickenson
  • BristolMyersSquibb
  • Celera (Quest Diagnostics)
  • Celldex Therapeutics
  • Claritas Genomics
  • CuraGen
  • Foundation Medicine
  • Eli Lilly
  • ELDA BioTech
  • Eisai
  • Genelex
  • GlaxoSmithKline
  • HalioDx
  • Illumina
  • InterGenetics
  • Johnson & Johnson
  • Merck
  • Myriad
  • Nodality
  • Novartis
  • Pfizer
  • Qiagen
  • Roche Molecular Diagnostics
  • Sanofi
  • Siemens Healthcare Diagnostics
  • Takeda
  • Thermo Fisher Scientific
  • Ventana (Roche)
  • Vertex Pharmaceuticals

Who should read this report?

  • Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
  • Industry professionals and business strategists will discover key information to propel their policies
  • Investors will gain inside information to dominant players in the industry and future forecasts
  • Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment

This report will tell you if the companies mentioned are:

  • Strong, competitive players
  • Pooling their resources for specific growth and therapeutic areas
  • Investing strategically in R&D
  • Have a history of strategic M&A activity

This detailed report is supported with over 365 tables & figures over 397 pages and profiles the main pharmacos in personalized medicine.


Additional information

Licence Types

Enterprise Wide Licence, Mid Level Licence (up to 10 people), Single User Licence